An Angiotensin Converting-Enzyme Inhibitor to Identify and Treat Vasoconstrictor and Volume Factors in Hypertensive Patients

New England Journal of Medicine

Volumn 291, Issue 16, 1974, Pages 817-821

  Gavras, Haralambos ^a   Brunner, Hans R ^a   Laragh, John H ^a   Sealey, Jean E ^a   Gavras, Irene ^a   Vukovich, Robert A ^a  

^a New York Presbyterian Columbia University Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; OLIGOPEPTIDE; RENIN; SODIUM;

ADOLESCENT; ADULT; ARTICLE; BLOOD; BLOOD PRESSURE; BLOOD VOLUME; DIET THERAPY; DRUG EFFECT; ENZYMOLOGY; FEMALE; HUMAN; HYPERTENSION; MALE; MALIGNANT HYPERTENSION; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; RENOVASCULAR HYPERTENSION; TIME; URINE;

ADOLESCENT; ADULT; ALDOSTERONE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD VOLUME; DIURETICS; FEMALE; HUMANS; HYPERTENSION; HYPERTENSION, MALIGNANT; HYPERTENSION, RENAL; MALE; MIDDLE AGED; OLIGOPEPTIDES; RENIN; SODIUM; TIME FACTORS;

EID: 0016395809     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM197410172911603     Document Type: Article

References (14)

1. Ondetti AM, Williams NJ, Sabo EF, et al. Angiotensin-converting enzyme inhibitors from the venom of bothrops jaracaca: isolation, elucidation of structure, and synthesis. Biochemistry 10: 4033–4039, 1971
2. Collier JG, Robinson BF, Vane JR: Reduction of pressor effects of angiotensin I in man by synthetic nonapeptide (B.P.P.9a or SQ 20881) which inhibits converting enzyme. Lancet 1: 72–74, 1973
3. Buhler FR, Laragh JH, Vaughan ED Jr, et al: Antihypertensive action of propranolol: specific antirenin responses in high and normal renin forms of essential, renal, renovascular and malignant hypertension. Am J Cardiol 32: 511–522, 1973
4. Miller ED Jr, Samuels AJ, Haber E, et al: Inhibition of angiotensin conversion in experimental renovascular hypertension. Science 177: 1108–1109, 1972
5. Krieger EM, Salgado HC, Assam CJ, et al: Potential screening test for detection of overactivity of renin-angiotensin system. Lancet 1: 269–271, 1971
6. Brunner HR, Gavras H, Laragh JH, et al: Angiotensin-II blockade in man by Sar1-ala8-angiotensin II for understanding and treatment of high blood pressure. Lancet 2: 1045–1048, 1973
7. Hypertension in man, exposure of the renin and sodium components using angiotensin II blockade. Circ Res (in press)
8. Gavras H, Brunner HR, Laragh JH, et al: Angiotensin II blockade, renin secretion and sodium balance in hypertensive man. Circulation 48: Suppl 4: 166, 1973
9. Gavras H, Brunner HR, Vaughan ED Jr, et al: Angiotensin-sodium interaction in blood pressure maintenance of renal hypertensive and normotensive rats. Science 180: 1369–1372, 1973
10. Johnson JA, Davis JO: Effects of a specific competitive antagonist of angiotensin II on arterial pressure and adrenal steroid secretion in dogs. Circ Res 32: Suppl 1: 159–168, 1973
11. Sealey JE, Laragh JH, Gerten-Banes J, et al: The measurement of plasma renin activity in man. Hypertension Manual. Edited by JH Laragh, New York, Yorke Medical Books, 1974, pp 621–640
12. Bühler FR, Sealey JE, Laragh JH: Radioimmunoassay of plasma aldosterone, Hypertension Manual. Edited by JH Laragh, New York, Yorke Medical Books, 1974, pp 665–669
13. Laragh JH: Vasoconstriction-volume analysis for understanding and treating hypertension: the use of renin and aldosterone profiles. Am J Med 55: 261–274, 1973
14. Schalekamp MA, Beevers DG, Briggs JD, et al: Hypertension in chronic renal failure: an abnormal relationship between sodium and the renin-angiotensin system. Am J Med 55: 379–390, 1973